Yingli Pharma brings small molecule research to the US in new pact with MD Anderson; UCB’s psoriatic arthritis drug shows positive PhIII results

Shanghai biotech Yingli Pharma wants to bring its small molecule drug research global — and a new pact with MD Anderson will help it get there.

Yingli and MD Anderson have inked a 5-year collaboration deal that will put its cancer candidates — some of which...

Click to view original post